Aurinia board explores strategic alternatives including sale; two directors resign after vote shortfall

Aurinia Pharmaceuticals Inc.

Board initiated exploration of strategic alternatives including sale, merger, or other transaction.
Retained JP Morgan as financial advisor; Skadden Arps and Borden Ladner Gervais as legal counsel.
Directors George Milne and Joseph Hagan resigned effective June 29 after less-than-majority support at AGM.
Korn Ferry engaged to search for two new board members.
No timetable set; no assurance of any transaction outcome.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

George Milne

director

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2023-06-29
Filed: July 3, 2023, 7:59 PM ET

the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.

Departed

Joseph P. Hagan

director

AUPH · Aurinia Pharmaceuticals Inc.

Effective: 2023-06-29
Filed: July 3, 2023, 7:59 PM ET

the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

George Milne resigned as director at Aurinia Pharmaceuticals Inc..

Action: resigned
Role: director

Exact text from the filing

the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph P. Hagan resigned as director at Aurinia Pharmaceuticals Inc..

Action: resigned
Role: director

Exact text from the filing

the Board, following the deliberation process outlined in the Company’s Majority Voting Policy, determined to accept the resignations of Dr. Milne and Mr. Hagan effective June 29, 2023.

View on SEC.gov

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-23-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.